Transcenta OK’d to Start US Trials of MASP2 mAb for Kidney Disease

Suzhou Transcenta was approved to start US trials of its MASP2 targeting mAb that aims to prevent the inflammation and tissue damage mediated by lectin pathway complement activation. MASP2 (mannose-binding protein-associated serine protease 2) is a key enzyme in the lectin pathway initiation of complement activation. Activating the lectin pathway contributes to immunoglobulin A nephropathy, along with hematopoietic stem-cell transplantation–associated thrombotic microangiopathy. About 30% to 45% of patients with IgA nephropathy develop end-stage kidney disease, an unmet need. Transcenta discovered TST004 in-house. More details....

Stock Symbol: (HK: 06628)

Share this with colleagues: